Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

This study has been terminated.
(A total of three parts were planned for this study. The sponsor funded only Part 1, so that neither Part 2 nor Part 3 of this study has been conducted.)
CrystalGenomics, Inc.
Information provided by (Responsible Party):
Carsten Skarke, University of Pennsylvania
ClinicalTrials.gov Identifier:
First received: October 24, 2008
Last updated: February 5, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2013
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Hirankarn S, Barrett JS, Alamuddin N, FitzGerald GA, Skarke C. GCG100649, a novel cyclooxygenase-2 inhibitor, exhibits a drug disposition profile in healthy volunteers compatible with high affinity to carbonic anhydrase-I/II: Preliminary dose-exposure relationsships to define clinical development strategies. 2013 Oct; 2 (4):379-386 Clin Pharm Drug Development.